CLEC4M — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL420952	0.79	2/20
SCHEMBL445262	0.79	2/20
SCHEMBL445263	0.79	2/20
SCHEMBL445806	0.65	2/20
SCHEMBL445808	0.65	2/20
SCHEMBL5462298	0.61	2/20
SCHEMBL5462301	0.61	2/20
SCHEMBL5457416	0.60	2/20
SCHEMBL5457418	0.60	2/20
SCHEMBL3400157	0.52	2/20
SCHEMBL418906	0.51	2/20
SCHEMBL448122	0.51	2/20
SCHEMBL5143182	0.51	2/20
SCHEMBL5143183	0.51	2/20
SCHEMBL420803	0.46	2/20
SCHEMBL447823	0.46	2/20
SCHEMBL420954	0.45	2/20
SCHEMBL445554	0.45	2/20
SCHEMBL1244789	0.80	1/20
SCHEMBL4510415	0.79	1/20

Clinical trials — most relevant to CLEC4M by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Multiple CAR-T Cell Therapy Targeting AML	PHASE1/PHASE2	RECRUITING
Fostamatinib for Hospitalized Adults With COVID-19	PHASE2	COMPLETED
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders	PHASE2	COMPLETED
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia	PHASE1/PHASE2	RECRUITING
TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC	PHASE2	RECRUITING
Universal CAR-T Cells Targeting AML	PHASE1	RECRUITING
Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia	PHASE1	RECRUITING
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma	PHASE1	COMPLETED
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies	EARLY_PHASE1	UNKNOWN
Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients	nan	UNKNOWN
Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease	nan	COMPLETED
Mechanism of DCs Dysfunction in Chronic HBV Infection	nan	UNKNOWN
Postprandial Monocyte Study	nan	COMPLETED
Prediction of Disease Severity in Young Children Presenting With Acute Febrile Illness in Resource-limited Settings	nan	COMPLETED
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection	nan	COMPLETED
Circular RNA and Chemerin in Breast Cancer Patient	nan	UNKNOWN
Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis	nan	COMPLETED
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in HR-HPV Clearance	nan	UNKNOWN
Prospective Lung Transplant Database for Genetic Research	nan	COMPLETED
Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients	nan	UNKNOWN
Urinary G3BP as a Novel Biomarker in Lupus Nephritis	nan	NOT_YET_RECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Development and Validation of a Nomogram for Predicting Surgery in Newly-diagnosed Crohn's Disease: a Retrospective Cohort Study	nan	COMPLETED
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection	nan	COMPLETED
Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1	nan	UNKNOWN
Identification of Genes Predisposing to Atherosclerosis	nan	COMPLETED
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease	nan	COMPLETED
Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry	nan	UNKNOWN
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CLEC4M binder may also engage these)

Protein	Name	Similarity
Q8HY11	—	1.000	Q8HY11 →
Q8HY10	—	1.000	Q8HY10 →
Q8HY01	—	1.000	Q8HY01 →
Q95J96	—	1.000	Q95J96 →
Q8HY02	—	1.000	Q8HY02 →
Q8HY06	—	1.000	Q8HY06 →
Q8HXZ7	—	1.000	Q8HXZ7 →
Q8HY12	—	0.999	Q8HY12 →
P60883	—	0.999	P60883 →
Q8HY00	—	0.999	Q8HY00 →
Q8HXZ8	—	0.997	Q8HXZ8 →
CD209	CD209 antigen	0.997	landscape →
Q8HY04	—	0.994	Q8HY04 →
Q8HYC0	—	0.994	Q8HYC0 →
Q8HY03	—	0.994	Q8HY03 →
Q95LC6	—	0.993	Q95LC6 →
Q8CJ91	—	0.980	Q8CJ91 →
Q6ZS10	—	0.978	Q6ZS10 →
Q9UQP3	—	0.975	Q9UQP3 →
E9Q0N2	—	0.973	E9Q0N2 →
B4DH59	—	0.972	B4DH59 →
P20693	—	0.969	P20693 →
P0CG38	—	0.969	P0CG38 →
A5A3E0	—	0.968	A5A3E0 →
Q8MIS5	—	0.967	Q8MIS5 →
Q80Z71	—	0.967	Q80Z71 →
Q9EQ09	—	0.966	Q9EQ09 →
B5DUH6	—	0.965	B5DUH6 →
Q91ZW8	—	0.964	Q91ZW8 →
Q8N1N0	—	0.964	Q8N1N0 →